Literature DB >> 31038409

LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.

Erin L Shropshire1, Mohammad Chaudhry1, Chad M Miller1, Brian C Allen1, Erol Bozdogan1, Diana M Cardona1, Lindsay Y King1, Gemini L Janas1, Richard K Do1, Charles Y Kim1, James Ronald1, Mustafa R Bashir1.   

Abstract

Background In 2017, the Liver Imaging Reporting and Data System (LI-RADS) included an algorithm for the assessment of hepatocellular carcinoma (HCC) treated with local-regional therapy. The aim of the algorithm was to enable standardized evaluation of treatment response to guide subsequent therapy. However, the performance of the algorithm has not yet been validated in the literature. Purpose To evaluate the performance of the LI-RADS 2017 Treatment Response algorithm for assessing the histopathologic viability of HCC treated with bland arterial embolization. Materials and Methods This retrospective study included patients who underwent bland arterial embolization for HCC between 2006 and 2016 and subsequent liver transplantation. Three radiologists independently assessed all treated lesions by using the CT/MRI LI-RADS 2017 Treatment Response algorithm. Radiology and posttransplant histopathology reports were then compared. Lesions were categorized on the basis of explant pathologic findings as either completely (100%) or incompletely (<100%) necrotic, and performance characteristics and predictive values for the LI-RADS Treatment Response (LR-TR) Viable and Nonviable categories were calculated for each reader. Interreader association was calculated by using the Fleiss κ. Results A total of 45 adults (mean age, 57.1 years ± 8.2; 13 women) with 63 total lesions were included. For predicting incomplete histopathologic tumor necrosis, the accuracy of the LR-TR Viable category for the three readers was 60%-65%, and the positive predictive value was 86%-96%. For predicting complete histopathologic tumor necrosis, the accuracy of the LR-TR Nonviable category was 67%-71%, and the negative predictive value was 81%-87%. By consensus, 17 (27%) of 63 lesions were categorized as LR-TR Equivocal, and 12 of these lesions were incompletely necrotic. Interreader association for the LR-TR category was moderate (κ = 0.55; 95% confidence interval: 0.47, 0.67). Conclusion The Liver Imaging Reporting and Data System 2017 Treatment Response algorithm had high predictive value and moderate interreader association for the histopathologic viability of hepatocellular carcinoma treated with bland arterial embolization when lesions were assessed as Viable or Nonviable. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Gervais in this issue.

Entities:  

Mesh:

Year:  2019        PMID: 31038409      PMCID: PMC6614909          DOI: 10.1148/radiol.2019182135

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  16 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy.

Authors:  Ron C Gaba; R Peter Lokken; Ryan M Hickey; Andrew J Lipnik; Robert J Lewandowski; Riad Salem; Daniel B Brown; T Gregory Walker; James E Silberzweig; Mark Otto Baerlocher; Ana Maria Echenique; Mehran Midia; Jason W Mitchell; Siddharth A Padia; Suvranu Ganguli; Thomas J Ward; Jeffrey L Weinstein; Boris Nikolic; Sean R Dariushnia
Journal:  J Vasc Interv Radiol       Date:  2017-06-29       Impact factor: 3.464

3.  Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.

Authors:  Matthew S Davenport; Shokoufeh Khalatbari; Peter S C Liu; Katherine E Maturen; Ravi K Kaza; Ashish P Wasnik; Mahmoud M Al-Hawary; Daniel I Glazer; Erica B Stein; Jeet Patel; Deepak K Somashekar; Benjamin L Viglianti; Hero K Hussain
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

Review 4.  2017 Version of LI-RADS for CT and MR Imaging: An Update.

Authors:  Khaled M Elsayes; Jonathan C Hooker; Michelle M Agrons; Ania Z Kielar; An Tang; Kathryn J Fowler; Victoria Chernyak; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Aya Kamaya; Elizabeth M Hecht; Claude B Sirlin
Journal:  Radiographics       Date:  2017 Nov-Dec       Impact factor: 5.333

5.  The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.

Authors:  Renumathy Dhanasekaran; Vinit Khanna; David A Kooby; James R Spivey; Samir Parekh; Stuart J Knechtle; John D Carew; John S Kauh; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2010-08       Impact factor: 3.464

Review 6.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 7.  Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.

Authors:  Laura Kulik; Julie K Heimbach; Feras Zaiem; Jehad Almasri; Larry J Prokop; Zhen Wang; M Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2017-11-29       Impact factor: 17.425

8.  Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation.

Authors:  Michael S Hodavance; Eric M Vikingstad; Andrew S Griffin; Waleska M Pabon-Ramos; Carl L Berg; Paul V Suhocki; Charles Y Kim
Journal:  J Vasc Interv Radiol       Date:  2015-10-21       Impact factor: 3.464

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.

Authors:  Zhihong Weng; Judith Ertle; Shaoping Zheng; Thomas Lauenstein; Stefan Mueller; Andreas Bockisch; Guido Gerken; Dongliang Yang; Joerg F Schlaak
Journal:  Oncol Lett       Date:  2013-10-10       Impact factor: 2.967

View more
  22 in total

Review 1.  Artificial intelligence in assessment of hepatocellular carcinoma treatment response.

Authors:  Bradley Spieler; Carl Sabottke; Ahmed W Moawad; Ahmed M Gabr; Mustafa R Bashir; Richard Kinh Gian Do; Vahid Yaghmai; Radu Rozenberg; Marielia Gerena; Joseph Yacoub; Khaled M Elsayes
Journal:  Abdom Radiol (NY)       Date:  2021-03-31

Review 2.  LI-RADS: Future Directions.

Authors:  Victoria Chernyak; Claude B Sirlin
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 3.  LI-RADS and transplantation: challenges and controversies.

Authors:  Guilherme M Cunha; Dorathy E Tamayo-Murillo; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2021-01

4.  Moving Away from Uncertainty: A Potential Role for Ancillary Features in LI-RADS Treatment Response.

Authors:  Richard K Do; Mishal Mendiratta-Lala
Journal:  Radiology       Date:  2020-07-21       Impact factor: 11.105

5.  LI-RADS Version 2018 Treatment Response Algorithm: The Evidence Is Accumulating.

Authors:  Richard K Do; Mishal Mendiratta-Lala
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

6.  LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.

Authors:  Ali Pirasteh; E Aleks Sorra; Hector Marquez; Robert C Sibley; Julia R Fielding; Abhinav Vij; Nicole E Rich; Ana Arroyo; Adam C Yopp; Gaurav Khatri; Amit G Singal; Takeshi Yokoo
Journal:  Abdom Radiol (NY)       Date:  2021-03-23

Review 7.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

Review 8.  LI-RADS treatment response assessment of combination locoregional therapy for HCC.

Authors:  Marielia Gerena; Christopher Molvar; Mark Masciocchi; Sadhna Nandwana; Carl Sabottke; Bradley Spieler; Rishi Sharma; Leo Tsai; Ania Kielar
Journal:  Abdom Radiol (NY)       Date:  2021-06-13

Review 9.  PI-RADS: what is new and how to use it.

Authors:  Silvina P Dutruel; Sunil Jeph; Daniel J A Margolis; Natasha Wehrli
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 10.  LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.

Authors:  Roopa Ram; Rony Kampalath; Anuradha S Shenoy-Bhangle; Sandeep Arora; Ania Z Kielar; Mishal Mendiratta-Lala
Journal:  Abdom Radiol (NY)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.